Citation: D. Pim et al., ALTERNATIVELY SPLICED HPV-18 E6-ASTERISK PROTEIN INHIBITS E6 MEDIATEDDEGRADATION OF P53 AND SUPPRESSES TRANSFORMED-CELL GROWTH, Oncogene, 15(3), 1997, pp. 257-264
Citation: L. Grifoni et al., SI3N4 THICKNESS AND ITS OXIDATION TIME INFLUENCE ON O N/O DRAM CELL PERFORMANCE/, Journal of non-crystalline solids, 216, 1997, pp. 202-208
Citation: P. Massimi et al., HUMAN-PAPILLOMAVIRUS TYPE-16 E7 BINDS TO THE CONSERVED CARBOXY-TERMINAL REGION OF THE TATA BOX-BINDING PROTEIN AND THIS CONTRIBUTES TO E7 TRANSFORMING ACTIVITY, Journal of General Virology, 78, 1997, pp. 2607-2613
Citation: V. Bouvard et al., CHARACTERIZATION OF CELLULAR-CHANGES WHICH INFLUENCE PROGRESSION OF HUMAN PAPILLOMAVIRUS TYPE-16 IMMORTALIZED KERATINOCYTES TO ANCHORAGE-INDEPENDENT PHENOTYPE, International journal of oncology, 8(1), 1996, pp. 159-167
Citation: M. Thomas et al., HPV-18 E6 INHIBITS P53 DNA-BINDING ACTIVITY REGARDLESS OF THE OLIGOMERIC STATE OF P53 OR THE EXACT P53 RECOGNITION SEQUENCE, Oncogene, 13(3), 1996, pp. 471-480
Citation: A. Storey et al., CONDITIONAL IMMORTALIZATION OF PRIMARY-CELLS BY HUMAN PAPILLOMAVIRUS TYPE-18 E6 AND EJ-RAS DEFINES AN E6 ACTIVITY IN G(0) G(1) PHASE WHICH CAN BE SUBSTITUTED FOR MUTATIONS IN P53/, Oncogene, 11(4), 1995, pp. 653-661
Citation: M. Thomas et al., HPV-18 E6 MEDIATED INHIBITION OF P53 DNA-BINDING ACTIVITY IS INDEPENDENT OF E6 INDUCED DEGRADATION, Oncogene, 10(2), 1995, pp. 261-268
Authors:
STOREY A
PICCINI A
MASSIMI P
BOUVARD V
BANKS L
Citation: A. Storey et al., MUTATIONS IN THE HUMAN PAPILLOMAVIRUS TYPE-16 E2 PROTEIN IDENTIFY A REGION OF THE PROTEIN INVOLVED IN BINDING TO E1 PROTEIN, Journal of General Virology, 76, 1995, pp. 819-826
Citation: A. Piccini et al., MUTATIONS IN THE HUMAN PAPILLOMAVIRUS TYPE-16 E2 PROTEIN IDENTIFY MULTIPLE REGIONS OF THE PROTEIN INVOLVED IN BINDING TO E1, Journal of General Virology, 76, 1995, pp. 2909-2913
Authors:
PIM D
STOREY A
THOMAS M
MASSIMI P
BANKS L
Citation: D. Pim et al., MUTATIONAL ANALYSIS OF HPV-18 E6 IDENTIFIES DOMAINS REQUIRED FOR P53 DEGRADATION IN-VITRO, ABOLITION OF P53 TRANSACTIVATION IN-VIVO AND IMMORTALIZATION OF PRIMARY BMK CELLS, Oncogene, 9(7), 1994, pp. 1869-1876